SEEBRI NEOHALER
LOE ApproachingNDAINHALATIONPOWDER
Approved
Oct 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEEBRI NEOHALER is an inhalation powder product approved by Novartis in October 2015 for chronic respiratory disease management. The specific indication, mechanism of action, and generic name are not publicly detailed in available data. It represents a small-molecule respiratory therapeutic delivered via dry powder inhaler technology.
LOE Approaching2.2 years to LOE
Product approaching loss of exclusivity with modest competitive pressure (15-drug landscape), suggesting brand defense and lifecycle extension initiatives will dominate team priorities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on SEEBRI NEOHALER at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.